Pleasing Signs As A Number Of Insiders Buy BioAtla Stock
| BCAB Stock | USD 1.67 0.01 0.60% |
About 64% of all Bioatla's investors are looking to take a long position. The analysis of the overall investor sentiment regarding Bioatla suggests that some traders are interested. The current market sentiment, together with Bioatla's historical and current headlines, can help investors time the market. In addition, many technical investors use Bioatla stock news signals to limit their universe of possible portfolio assets.
Bioatla |
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...
Read at simplywall.st
 |
Bioatla Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Bioatla can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bioatla Fundamental Analysis
We analyze Bioatla's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioatla using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioatla based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Bioatla is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Bioatla Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Bioatla stock to make a market-neutral strategy. Peer analysis of Bioatla could also be used in its relative valuation, which is a method of valuing Bioatla by comparing valuation metrics with similar companies.
Peers
Bioatla Related Equities
| ERAS | Erasca | 12.94 | ||||
| DSGN | Design Therapeutics | 4.67 | ||||
| PMVP | Pmv Pharmaceuticals | 4.32 | ||||
| IKNA | Ikena Oncology | 2.37 | ||||
| KYMR | Kymera Therapeutics | 1.90 | ||||
| RZLT | Rezolute | 1.19 | ||||
| AVTE | Aerovate Therapeutics | 1.14 | ||||
| OLMA | Olema Pharmaceuticals | 0.89 | ||||
| FHTX | Foghorn Therapeutics | 0.50 | ||||
| STTK | Shattuck Labs | 0.91 | ||||
| GLUE | Monte Rosa | 1.35 | ||||
| ACRV | Acrivon Therapeutics, | 1.85 | ||||
| IPSC | Century Therapeutics | 2.33 | ||||
| NAUT | Nautilus Biotechnology | 2.61 | ||||
| NRIX | Nurix Therapeutics | 2.80 | ||||
| ANTX | AN2 Therapeutics | 4.19 | ||||
| CCCC | C4 Therapeutics | 5.49 | ||||
| ADAG | Adagene | 6.41 | ||||
| PASG | Passage Bio | 10.62 |
Complementary Tools for Bioatla Stock analysis
When running Bioatla's price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |